Publications by authors named "Jonathan Finlayson"

Claim this Profile
E
Evaluating the druggability of TrmD, a potential antibacterial target, through design and microbiological profiling of a series of potent TrmD inhibitors.
Andrew J Wilkinson, Nicola Ooi, Jonathan Finlayson, Victoria E Lee, David Lyth

Bioorg Med Chem Lett· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and structure-activity relationships of a novel oxazolidinone class of bacterial type II topoisomerase inhibitors.
Amanda Lyons, James Kirkham, Kevin Blades, David Orr, Elizabeth Dauncey, Jonathan Finlayson

Bioorg Med Chem Lett· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic benefits of 3,4-dimethoxy substitution of a phenyl ring and design of isosteres yielding orally available cathepsin K inhibitors.
James J Crawford, Peter W Kenny, Jonathan Bowyer, Calum R Cook, Jonathan E Finlayson

J Med Chem· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.
Alexander G Dossetter, Jonathan Bowyer, Calum R Cook, James J Crawford, Jonathan E Finlayson

Bioorg Med Chem Lett· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis.
Alexander G Dossetter, Howard Beeley, Jonathan Bowyer, Calum R Cook, James J Crawford, Jonathan E Finlayson

J Med Chem· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide (AZD6703), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases.
Dearg S Brown, John G Cumming, Paul Bethel, Jonathan Finlayson, Stefan Gerhardt

Bioorg Med Chem Lett· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The benzyne Fischer-indole reaction.
Donald McAusland, Sangwon Seo, Didier G Pintori, Jonathan Finlayson, Michael F Greaney

Org Lett· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis